Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome

Endocrine Reviews

Volumn 22, Issue 1, 2001, Pages 75-110

  Lacroix, A ^a   N'Diaye, N ^a   Tremblay, J ^a   Hamet, P ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ARGIPRESSIN RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE; CHORIONIC GONADOTROPIN RECEPTOR; CORTICOTROPIN; CORTICOTROPIN RECEPTOR; GASTRIC INHIBITORY POLYPEPTIDE; GONADORELIN AGONIST; HYDROCORTISONE; LEPTIN RECEPTOR; LEUPRORELIN; LEVOTHYROXINE; LUTEINIZING HORMONE RECEPTOR; OCTREOTIDE; PROPRANOLOL; SEROTONIN; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SOMATOSTATIN; VASOPRESSIN RECEPTOR;

ADRENAL CELL; ADRENAL HYPERPLASIA; ADRENAL TUMOR; ADRENALECTOMY; CUSHING DISEASE; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HYDROCORTISONE RELEASE; HYPERCORTISOLISM; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STEROIDOGENESIS;

ADRENAL GLAND DISEASES; CUSHING SYNDROME; HORMONES; HUMANS; RECEPTORS, CELL SURFACE;

EID: 0035118956     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.22.1.75     Document Type: Review

References (406)

1. Cushing's syndrome
2. The adrenal cortex
3. Glucocorticoid action and the clinical features of Cushing's syndrome
4. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states
5. Cushing's syndrome secondary to ectopic cortisol production by an ovarian carcinoma
6. A patient with hypocortisolism and Cushing's syndrome-like manifestations: Cortisol hyperreactive syndrome
7. Normocortisolemic Cushing's syndrome initially presenting with increased glucocorticoid receptor numbers
8. Abnormal hormone responses of an adrenocortical cancer adenyl cyclase
9. Abnormal control in the neoplastic adrenal cortex
10. Hormone receptor abnormalities in adrenal Cushing's syndrome
11. Intraadrenal interactions in the regulation of adrenocortical steroidogenesis
12. Immune-endocrine interactions in the mammalian adrenal gland: Facts and hypotheses
13. Vasopressin and its neurophysin
14. Corticotropin-releasing hormone: Basic physiology and clinical applications
15. Expression cloning of a human corticotropin-releasing-factor receptor
16. Cloning and characterization of the human V3 pituitary vasopressin receptor
17. Proopiomelanocortin-derived peptides
18. Role of VIP, PACAP, and related peptides in the regulation of the hypothalamo-pituitary-adrenal axis
19. Stimulation by peptide histidine methionine (PHM) of adrenocorticotropin secretion in patients with Cushing's disease: A comparison with the effect of vasoactive intestinal peptide (VIP) and a study on the effect of combined administration of corticotropin-releasing hormone with PHM or VIP
20. Effect of acute systemic inflammatory response and cytokines on the transcription of the genes encoding cyclooxygenase enzymes (COX-1 and COX-2) in the rat brain
21. Corticotropin-releasing hormone is produced by rat corticotropes and modulates ACTH secretion in a paracrine/autocrine fashion
22. The cloning of a family of genes that encode the melanocortin receptors
23. Genomic structure and promoter characterization of the human ACTH receptor gene
24. Regulation of the synthesis of steroidogenic enzymes in adrenal cortical cells by ACTH
25. The acute and chronic effects of adrenocorticotropin on the levels of messenger ribonucleic acid and protein of steroidogenic enzymes in rat adrenal in vivo
26. Molecular biology of steroid hormone synthesis
27. Regulation of the acute production of steroids in steroidogenic cells
28. The purification, cloning, and expression of a novel luteinizing hormone-induced mitochondrial protein in MA-10 mouse Leydig tumor cells. Characterization of the steroidogenic acute regulatory protein (StAR)
29. Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis
30. The pathophysiology and genetics of congenital lipoid adrenal hyperplasia. International Congenital Lipoid Adrenal Hyperplasia Consortium
31. Targeted disruption of the mouse gene encoding steroidogenic acute regulatory protein provides insights into congenital lipoid adrenal hyperplasia
32. Structure and function of the peripheral-type benzodiazepine receptor in steroidogenic cells
33. In vivo regulation of peripheral-type benzodiazepine receptor and glucocorticoid synthesis by Ginkgo biloba extract EGb 761 and isolated ginkgolides
34. In vivo effects of adrenocorticotropin on c-jun, jun-B, c-fos and fos-B in rat adrenal
35. ACTH-related peptides: Receptors and signal transduction systems involved in their neurotrophic and neuroprotective actions
36. Corticotropin positively regulates its own receptors and cAMP response in cultured bovine adrenal cells
37. ACTH induces up-regulation of ACTH receptor mRNA in mouse and human adrenocortical cell lines
38. Hormonal regulation of messenger ribonucleic acids for P450 scc (cholesterol side-chain cleavage enzyme) and P450c17 (17α-hydroxylase/17,20lyase) in cultured human fetal adrenal cells
39. Neuroendocrine regulation of the hypothalamic pituitary adrenal axis by the nurr1/nur77 subfamily of nuclear receptors
40. Regulation of expression of the steroidogenic acute regulatory protein (StAR) gene: A central role for steroidogenic factor 1
41. Steroidogenic factor 1: A key determinant of endocrine development and function
42. The nuclear receptor steroidogenic factor 1 acts at multiple levels of the reproductive axis
43. Adrenocorticotropic hormone regulates the activities of the orphan nuclear receptor Nur77 through modulation of phosphorylation
44. The orphan nuclear receptor NGFI-B regulates expression of the gene encoding steroid 21-hydroxylase
45. Activation of CYP11A and CYP11B gene promoters by the steroidogenic cell-specific transcription factor, Ad4BP
46. Contribution of Ad4BP, a steroidogenic cell-specific transcription factor, to regulation of the human CYP11A and bovine CYP11B genes through their distal promoters
47. Regulatory mechanisms of cAMP-dependent and cell-specific expression of human steroidogenic cytochrome P450 scc (CYP11A1) gene
48. Steroidogenic factor-1 binding and transcriptional activity of the cholesterol sidechain cleavage promoter in rat granulosa cells
49. The orphan nuclear receptor steroidogenic factor-1 regulates the cyclic adenosine 3′,5′-monophosphate-mediated transcriptional activation of rat cytochrome P450c17 (17α-hydroxylase/c17-c20 lyase)
50. Multiple orphan nuclear receptors converge to regulate rat P450c17 gene transcription: Novel mechanisms for orphan nuclear receptor action
51. Structures of regulatory regions in the human cytochrome P-450 scc (desmolase) gene
52. Transcriptional regulation of steroid hydroxylase genes by corticotropin
53. Members of the meis1 and pbx homeodomain protein families cooperatively bind a cAMP-responsive sequence (CRS1) from bovine CYP17
54. A cAMP-regulatory sequence (CRS1) of CYP17 is a cellular target for the homeodomain protein Pbx1
55. cAMP-dependent trans-activation involving the homeodomain protein Pbx1
56. Two Sp1-binding sites mediate cAMP-induced transcription of the bovine CYP11A gene through the protein kinase A signaling pathway
57. Mutually exclusive interactions of two nuclear orphan receptors determine activity of a cyclic adenosine 3′,5′-monophosphate-responsive sequence in the bovine CYP17 gene
58. Mutations in the activation function-2 core domain of steroidogenic factor-1 dominantly suppresses PKA-dependent transactivation of the bovine CYP17 gene
59. Regulation of the human P450 scc gene by steroidogenic factor 1 is mediated by CBP/p300
60. The bovine CYP17 promoter contains a transcriptional regulatory element cooperatively bound by tale homeodomain proteins
61. Novel dimeric Nur77 signaling mechanism in endocrine and lymphoid cells
62. Antagonism between Nur77 and glucocorticoid receptor for control of transcription
63. The role of SF-1/Ad4BP in the control of the bovine gene for the steroidogenic acute regulatory (StAR) protein
64. Unimpaired thymic and peripheral T cell death in mice lacking the nuclear receptor NGFI-B (Nur77)
65. A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation
66. The roles of steroidogenic factor 1 in endocrine development and function
67. Factors involved in the regulation of adrenocorticotropic hormone/β-lipotropic hormone
68. Regulation of adrenocortical function by vasopressin
69. Arginine vasopressin (AVP) and AVP-like immunoreactivity in peripheral tissues
70. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: Actions and mechanisms of action
71. Agonist-stimulated turnover of the phosphoinositides and the regulation of adrenocortical steroidogenesis
72. Vasopressin stimulates cortisol secretion and phosphoinositide catabolism in cultured bovine adrenal fasciculata/reticularis cells
73. Oxytocin and arginine vasopressin stimulate steroid secretion by the isolated perfused rat adrenal gland
74. Vasopressin induces breakdown of membrane phosphoinositides in adrenal glomerulosa and fasciculata cells
75. Vasopressin stimulates cortisol secretion from human adrenocortical tissue through activation of V1 receptors
76. Vasopressin stimulates steroid secretion in human adrenal glands: Comparison with angiotensin-II effect
77. Vasopressin: A potent autocrine/paracrine regulator of mammal adrenal functions
78. Specific vasopressin binding to rat adrenal glomerulosa cells. Relationship to inositol lipid breakdown
79. Variable expression of the V1 vasopressin receptor modulates the phenotypic response of steroid-secreting adrenocortical tumors
80. Abnormal adrenal and vascular responses to vasopressin mediated by a V1-vasopressin receptor in a patient with adrenocorticotropin-independent macronodular adrenal hyperplasia, Cushing's syndrome, and orthostatic hypotension
81. Molecular and functional characterization of V1b vasopressin receptor in rat adrenal medulla
82. Enhanced adrenocorticotrophic hormone and cortisol responses to corticotrophin-releasing hormone in central idiopathic diabetes insipidus
83. Effect of plasma osmolality on pituitary-adrenal responses to corticotropin-releasing hormone and atrial natriuretic peptide changes in central diabetes insipidus
84. Adrenergic and cholinergic regulation of cortisol secretion from the zona fasciculata/reticularis of bovine adrenal cortex
85. Catecholamines stimulate steroid secretion of dispersed fowl adrenocortical cells, acting through the β-receptor subtype
86. Propranolol therapy for ectopic beta-adrenergic receptors in adrenal Cushing's syndrome
87. Serotonergic regulation of adrenocortical function
88. Serotonin stimulates corticosteroid secretion by frog adrenocortical tissue in vitro
89. Serotonin-induced stimulation of cortisol secretion from human adrenocortical tissue is mediated through activation of a serotonin4 receptor subtype
90. Adrenal mast cells modulate vascular and secretory responses in the intact adrenal gland of the rat
91. Effect of the serotonin-4 receptor agonist zacopride on aldosterone secretion from the human adrenal cortex: In vivo and in vitro studies
92. The serotonin-4 receptor agonist cisapride and angiotensin-II exert additive effects on aldosterone secretion in normal man
93. Immunohistochemical and biochemical evidence for the presence of serotonin in amphibian adrenal chromaffin cells
94. Immunohistochemical and neurochemical evidence for the presence of serotonin in the adrenal medulla of the rat
95. Immunocytochemical distribution of serotonin and neuropeptide Y (NPY) in mouse adrenal gland
96. Cellular communication in the neuro-adrenocortical axis: Role of vasoactive intestinal polypeptide (VIP)
97. Adrenal vasoactive intestinal peptide participates in neonatal corticosteroid production in the rat
98. Adrenocorticotropin, vasoactive intestinal polypeptide, growth hormone-releasing factor, and dynorphin compete for common receptors in brain and adrenal
99. Vasoactive intestinal peptide potentiates and directly stimulates catecholamine secretion from rat adrenal chromaffin cells
100. Differential secretion of catecholamines in response to peptidergic and cholinergic transmitters in rat adrenals
101. Neuropeptide Y (NPY)- and vasoactive intestinal peptide (VIP)-induced aldosterone secretion by rat capsule/glomerular zone could be mediated by catecholamines via β 1 adrenergic receptors
102. Vasoactive intestinal peptide stimulation of aldosterone secretion by the rat adrenal cortex may be mediated by the local release of catecholamines
103. The role of neuropeptides in the regulation of adrenal vascular tone: Effects of vasoactive intestinal polypeptide, substance P, neuropeptide Y, neurotensin, Met-enkephalin, and Leu-enkephalin on perfusion medium flow rate in the intact perfused rat adrenal
104. Paracrine control of adrenal cortical function by medullary chromaffin cells
105. Angiotensin-II acts via the type 1 receptor to inhibit 17α-hydroxylase cytochrome P450 expression in ovine adrenocortical cells
106. + in H295R adrenocortical cells
107. Regulation of angiotensin II type 1 receptor mRNA and protein in angiotensin II-induced hypertension
108. Angiotensin II and the adrenal
109. Characterization and regulation of angiotensin and corticotropin receptors on cultured bovine adrenal cells
110. Characterization and regulation of the angiotensin II type-1 receptor (binding and mRNA) in human adrenal fasciculatareticularis cells
111. Locally generated angiotensin II in the adrenal gland regulates basal, corticotropin-, and potassium-stimulated aldosterone secretion
112. Renin-angiotensin system in the adrenal
113. The adrenal renin/angiotensin system in the rat
114. Dopamine selectively inhibits angiotensin II-induced aldosterone secretion by interacting with D-2 receptors
115. Effects of prolonged cysteamine administration on the rat adrenal cortex: Evidence that endogenous somatostatin is involved in the control of the growth and steroidogenic capacity of zona glomerulosa
116. The H295R human adrenocortical cell line contains functional atrial natriuretic peptide receptors that inhibit aldosterone biosynthesis
117. C-type natriuretic peptide as a possible local modulator of aldosterone secretion in bovine adrenal zona glomerulosa
118. Atrial natriuretic peptide inhibits calcium-induced steroidogenic acute regulatory protein gene transcription in adrenal glomerulosa cells
119. The role of endothelial cell products in the regulation of adrenocortical function: Actions of endothelin, nitric oxide, adrenomedullin and PAMP
120. The role of endothelins in the paracrine control of the secretion and growth of the adrenal cortex
121. Further investigations on the effects of neuropeptide Y on the secretion and growth of rat adrenal zona glomerulosa
122. Neuropeptide Y-related peptides and hypothalamo-pituitary-adrenal axis function
123. Obesity, leptin, and the brain
124. Role of leptin in the neuroendocrine response to fasting
125. Clinical review 94: What's in a name? In search of leptin's physiologic role
126. Leptin and leptin receptor expression in normal and neoplastic human pituitary: Evidence of a regulatory role for leptin on pituitary cell proliferation
127. Intact leptin receptor is selectively expressed in human fetal pituitary and pituitary adenomas and signals human fetal pituitary growth hormone secretion
128. Expression of Ob receptor in normal human adrenals: Differential regulation of adrenocortical and adrenomedullary function by leptin
129. Leptin receptors in the adrenal medulla of the rat
130. Leptin inhibits directly glucocorticoid secretion by normal human and rat adrenal gland
131. Leptin inhibition of the hypothalamic-pituitary-adrenal axis in response to stress
132. Effects of leptin on corticotropin-releasing factor (CRF) synthesis and CRF neuron activation in the paraventricular hypothalamic nucleus of obese (ob/ob) mice
133. Evidence for a novel peripheral action of leptin as a metabolic signal to the adrenal gland: Leptin inhibits cortisol release directly
134. Identification of targets of leptin action in rat hypothalamus
135. Acute effects of recombinant murine leptin on rat pituitary-adrenocortical function
136. Regulation of expression of ob mRNA and protein by glucocorticoids and cAMP
137. A regulatory loop between the hypothalamo-pituitary-adrenal (HPA) axis and circulating leptin: A physiological role of ACTH
138. Plasma leptin levels do not change in patients with Cushing's disease shortly after correction of hypercortisolism
139. Food-dependent Cushing's syndrome: Possible involvement of leptin in cortisol hypersecretion
140. Cytogenesis in the rat adrenal cortex: Evidence for an ACTH-induced centripetal cell migration from the zona glomerulosa
141. Histochemical and electron microscopic studies on the cells of the rat adrenal cortex in tissue culture
142. Corticosterone regulates cell proliferation and cytochrome P450 cholesterol side-chain cleavage enzyme messenger ribonucleic acid expression in primary cultures of fetal rat adrenals
143. Effects of corticosterone on adrenocorticotrophin-induced mitochondrial differentiation with special reference to 11 β- and 18-hydroxylation
144. Comparison of the ultrastructural and steroidogenic properties of mitochondria of fetal rat adrenals in tissue culture. A morphometric and a gas chromatographic analysis
145. Regulation of growth by ACTH in the Y-1 line of mouse adrenocortical cells
146. Regulation of primary response and specific genes in adrenal cells by peptide hormones and growth factors
147. Adrenocorticotropin induction of stress-activated protein in hte adrenal cortex in vivo neuroendocrine cells
148. Unmasking a growth-promoting effect of the adrenocorticotropic hormone in Y1 mouse adrenocortical tumor cells
149. Induction of FOS and JUN proteins by adrenocorticotropin and phorbol ester but not by 3′,5′-cyclic adenosine monophosphate derivatives
150. The regulation of AP-1 activity by mitogen-activated protein kinases
151. Angiotensin II activation of cyclin D1-dependent kinase activity
152. Unusual effect of prolonged vasoactive intestinal peptide (VIP) administration on the adrenal growth and corticosterone secretion in the rat
153. Evidence that endogenous vasoactive intestinal peptide (VIP) plays a role in the maintenance of the growth and steroidogenic capacity of rat adrenal zona glomerulosa
154. Insulin-like growth factors augment steroid production and expression of steroidogenic enzymes in human fetal adrenal cortical cells: Implications for adrenal androgen regulation
155. Parallel regulation of parentally imprinted H19 and insulin-like growth factor-II genes in cultured human fetal adrenal cells
156. Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: High 1GF-II expression in functional adrenocortical carcinomas
157. Recent advances in the pathogenesis of adrenocortical tumours
158. Regulation by adrenocorticotropin (ACTH), angiotensin II, transforming growth factor-β and insulin-like growth factor I of bovine adrenal cell steroidogenic capacity and expression of ACTH receptor steroidogenic acute regulatory protein cytochrome P450c17, and 3β-hydroxysteroid dehydrogenase
159. Growth-inhibitory effect of TGF-B on human fetal adrenal cells in primary monolayer culture
160. Proliferation and apoptosis in the human adrenal cortex during the fetal and perinatal periods: Implications for growth and remodeling
161. Epidemiology of Cushing's syndrome and subclinical disease
162. Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978)
163. Extensive personal experience: Adrenocortical tumors
164. Adrenocortical tumors: Recent advances in basic concepts and clinical management
165. Cushing's syndrome and the nodular adrenal gland
166. The diagnosis and differential diagnosis of Cushing's syndrome
167. The complex of myxomas, spotty pigmentation, and endocrine over-activity
168. Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2
169. Identification of a novel genetic locus for familial cardiac myxomas and Carney complex
170. Mutations of the gene encoding the protein kinase A Type 1-α regulatory subunit in patients with the Carney complex
171. Synaptophysin immunoreacfivity in primary pigmented nodular adrenocortical disease: Neuroendocrine properties of tumors associated with Carney complex
172. Paradoxical response to dexamethasone in the diagnosis of primary pigmented nodular adrenocortical disease
173. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome
174. Activating mutation in the stimulatory guanine nucleotide-binding protein in an infant with Cushing's syndrome and nodular adrenal hyperplasia
175. ACTH-independent massive bilateral adrenal disease AIMBAD: A subtype of Cushing's syndrome with major diagnostic and therapeutic implications
176. Clinical and genetic analysis of primary bilateral adrenal diseases (micro- and macronodular disease) leading to Cushing syndrome
177. Adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia: An unusual cause of Cushing's syndrome
178. Macronodular adrenal hyperplasia in Cushing disease
179. CT and MR imaging of massive macronodular adrenocortical disease: A rare cause of autonomous primary adrenal hypercortisolism
180. Familial adrenocorticotropin-independent Cushing's syndrome with bilateral macronodular adrenal hyperplasia
181. ACTH independent Cushing's syndrome occurring in siblings
182. Familial Cushing's syndrome secondary to bilateral macronodular hyperplasia
183. Hypercorticisme familial non ACTH dépendant par hyperplasie macronodulaire bilatérale des surrénales
184. Activation mutation in the stimulatory guanine nucleotide-binding protein in a woman with Cushing's syndrome by ACTH-independent macronodular adrenal hyperplasia
185. Multiple specific hormone receptors in the adenylate cyclase of an adrenocortical carcinoma
186. Ectopic β-adrenergic receptor binding sites. Possible molecular basis of aberrant catecholamine responsiveness of an adrenocortical tumor adenylate cyclase
187. Metabolic regulation and adenyl cyclase activity of adrenocortical carcinoma cultured cells
188. Studies on the adrenocorticotropic hormone-activated adenyl cyclase of a functional adrenal tumor
189. Ectopic alpha-adrenergic mediated accumulation of guanosine 3′,5′-monophosphate in isolated adrenocortical carcinoma cells
190. Characterization of ectopic α-adrenergic binding receptors of adrenocortical carcinoma cells
191. In vitro synthesis of steroids by a feminising adrenocortical carcinoma: Effect of prolactin and other protein hormones
192. Multiple hormone receptors in the adenylate cyclase of human adrenocortical tumors
193. Presence of ectopic β-adrenergic receptors on human adrenocortical cortisol-producing adenomas
194. Ectopic β-adrenergic receptors coupled to adenylate cyclase in human adrenocortical carcinomas
195. Human adrenocortical tumors: Alterations in membrane-bound hormone receptors and cAMP protein kinases
196. Testosterone-secreting virilizing adrenal adenoma with human chorionic gonadotrophin receptors and 21-hydroxylase deficiency
197. In vitro on an HCG responsive, testosterone secreting adrenal cortical adenoma
198. Cushing's syndrome secondary to an hCG/LH receptor-positive adrenal carcinoma presenting in the postpartum period
199. Aberrant interleukin-1 receptors in a cortisol-secreting adrenal adenoma causing Cushing's syndrome
200. Cushing syndrome with food-dependent periodic hormonogenesis
201. Gastric inhibitory polypeptide-dependent cortisol hypersecretion - A new cause of Cushing's syndrome
202. Food-dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide
203. Cushing's syndrome due to adrenal adenoma with persistent diurnal cortisol secretory rhythm
204. Gastric inhibitory polypeptide-dependent macro-nodular adrenal hyperplasia: A new etiology of Cushing's syndrome
205. Appetite comes with eating, cortisol too. A new cause of Cushing's syndrome
206. Food-dependent Cushing's syndrome: Characterization and functional role of gastric inhibitory polypeptide receptor in the adrenals of three patients
207. Asynchronous development of bilateral nodular adrenal hyperplasia in gastric inhibitory polypeptide-dependent Cushing's syndrome
208. Food-dependent Cushing's syndrome associated with the Carney complex
209. GIP-dependent adrenal Cushing's syndrome with incomplete suppression of ACTH
210. Adrenal GIP receptor overexpression in food-dependent Cushing's Syndrome
211. Food-dependent Cushing's syndrome resulting from abundant expression of gastric inhibitory polypeptide receptors in adrenal adenoma cells
212. Cushing's syndrome due to a gastric inhibitory polypeptide-dependent adrenal adenoma: Insights into hormonal control of adrenocortical tumorigenesis
213. Aberrant expression of the GIP (gastric inhibitory polypeptide) receptor in an adrenal cortical adenoma responsible for a case of food-dependent Cushing's syndrome
214. Un nouveau cas de syndrome de Cushing dependant de l'alimentation associé à un adénome surrénalien unique
215. Food-dependent androgen and cortisol secretion by a GIP-receptor expressive adrenocortical adenoma leading to hirsutism and subclinical Cushing's syndrome: In vivo and in vitro studies
216. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain
217. Hamster gastric inhibitory polypeptide receptor expressed in pancreatic islets and clonal insulin-secreting cells: Its structure and functional properties
218. Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent in-sulinotropic polypeptide receptor
219. Molecular cloning, functional expression, and signal transduction of the GIP-receptor cloned from a human insulinoma
220. Human gastric inhibitory polypeptide receptor: Cloning of the gene (GIPR) and cDNA
221. Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice
222. Adrenocortical overexpression of gastric inhibitory polypeptide receptor underlies food-dependent Cushing's syndrome
223. Syndrome de Cushing induit par le GIP: Expression clinique d'un récepteur ectopique
224. Cushing's disease: Role of feeding
225. Diurnal cortisol peaks and their relationships to meals
226. A mid-day surge in cortisol levels
227. Pituitary hormone release in response to food ingestion: Evidence for neuroendocrine signals from gut to brain
228. Tixocortol pivalate, a corticosteroid with no systemic glucocorticoid effect after oral, intrarectal, and intranasal application
229. Food-induced cortisol secretion is mediated by central α-1 adrenoceptor modulation of pituitary ACTH secretion
230. Hyperresponsiveness to lysine-vasopressin in Cushing's disease
231. Studies of ACTH secretion control in 116 cases of Cushing's syndrome
232. Vasopressin receptors modulate the pharmacological phenotypes of Cushing's syndrome
233. Responsiveness to corticotropin-releasing hormone and vasopressin in canine Cushing's syndrome
234. Responses of plasma ACTH, GH, LH and 11-hydroxycorticoste roids to various stimuli in patients with Cushing's syndrome
235. Cushing's syndrome due to huge nodular adrenocortical hyperplasia with fluctuation of urinary 17-OHCS excretion
236. Direct effect of lysine-vasopressin on cortisol production in isolated adrenal cells from nodular adrenocortical hyperplasia
237. Lysine vasopressin stimulation of cortisol secretion in patients with adrenocorticotropin-independent macronodular adrenal hyperplasia
238. Vasopressin-responsive adrenocortical tumor in a mild Cushing's syndrome: In vivo and in vitro studies
239. Oxytocin and vasopressin: Distinct receptors in myometrium
240. Adrenocorticotrophin-independent macronodular adrenal hyperplasia in a patient with lysine vasopressin responsiveness but insensitivity to gastric inhibitory polypeptide
241. Adrenocorticotropin-independent macronodular adrenocortical hyperplasia associated with multiple colon adenomas/carcinomas which showed a point mutation in the APC gene
242. In vivo and in vitro effects of AVP and V1a receptor antagonist on Cushing's syndrome due to ACTH-independent bilateral macronodular adrenocortical hyperplasia
243. Are ectopic or abnormal membrane hormone receptors frequently present in adrenal Cushing's Syndrome?
244. Immunoreactive vasopressin and oxytocin in hypothalamo-hypophysial portal blood of the Brattleboro and Long-Evans rat: Effect of adrenalectomy and dexamethasone
245. Abnormal membrane hormone receptors in subclinical bilateral macronodular adrenal hyperplasia
246. The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome
247. Desmopressin stimulation test for diagnosis of ACTH-dependent Cushing's syndrome
248. The desmopressin stimulation test in the differential diagnosis of Cushing's syndrome
249. Alpha-adrenergic stimulation of corticotropin secretion by a specific central mechanism in man
250. The lutropin/choriogonadotrepin receptor.. 4 years later
251. The beginning of a new era in reproductive biology and medicine: Expression of low levels of functional luteinizing hormone/human chorionic gonadotropin receptors in nongondal tissues
252. Novel presence of luteinizing hormone/chorionic gonadotropin receptors in human adrenal glands
253. Role of hCG in regulation of the fetal zone of the human fetal adrenal gland
254. Leuprolide acetate therapy in luteinizing hormone-dependent Cushing's syndrome
255. Cushing's syndrome and pregnancy
256. Cushing's syndrome and pregnancy
257. Cushing syndrome in pregnancy
258. Pregnancy complicated by Cushing's syndrome
259. Intercurrent Cushing's syndrome and pregnancy
260. Spontaneous remission of Cushing syndrome after termination of pregnancy
261. Exacerbation of Cushing's syndrome during pregnancy: Report of a case
262. Pregnancy in Cushing's syndrome
263. Pregnancy-induced Cushing's syndrome in multiple pregnancies
264. ACTH-independent Cushing's syndrome in pregnancy with spontaneous resolution after delivery: Control of the hypercortisolism with metyrapone
265. Cushing's syndrome complicating pregnancy. A case report
266. Spontaneous resolution of Cushing's syndrome after pregnancy
267. A gonadotrophin responsive testosterone producing adrenocortical adenoma and high gonadotrophin levels in an elderly woman
268. A gonadotrophin-responsive virilizing adrenal tumour identified as a mixed ganglioneuroma and adreno-cortical adenoma
269. Testosterone-secreting adrenal adenoma under gonadotropin control
270. A testosterone-producing adrenal cortical adenoma in an elderly woman
271. A gonadotropin-responsive adrenocortical adenoma
272. Virilizing adrenocortical adenoma responsive to gonadotrophin
273. A testosterone-secreting adrenal cortical adenoma
274. Effect of prolonged administration of the serotonin4 (5-HT4) receptor agonist cisapride on aldosterone secretion in healthy volunteers
275. Hypercorticism by bilateral adrenal hyperplasia with several paradoxical responses
276. Estradiol stimulates cortisol production by adrenal cells in estrogen-dependent primary adrenocortical nodular dysplasia
277. Paradoxical response to dexamethasone correlates with high expression of glucocorticoid receptors in primary pigmented nodular adrenocortical disease
278. Cortisol responsiveness to insulin-induced hypoglycemia in Cushing's syndrome with huge nodular adrenocortical hyperplasia
279. Detection of Ob-receptor in human adrenal neoplasms and effect of leptin on adrenal cell proliferation
280. Clinical evaluation of the presence of abnormal hormone receptors in adrenal Cushing's syndrome
281. Differential expression of prolactin receptor (PRLR) in normal and tumorous adrenal tissues: Separation of cellular endocrine compartments by laser capture microdissection (LCM)
282. Cloning, characterization and expression of a functional mouse ACTH receptor
283. Characterization of melanocortin receptor subtype expression in murine adipose tissues and in the 3T3-L1 cell line
284. A steroidogenic factor-1 binding element is essential for basal human ACTH receptor gene transcription
285. Three steroidogenic factor-1 binding elements are required for constitutive and cAMP-regulated expression of the human adrenocorticotropin receptor gene
286. Regulation of corticotropin receptor number and messenger RNA in cultured human adrenocorfical cells by corticotropin and angiotensin II
287. Regulation of bovine adrenal cell corticotropin receptor mRNA levels by corticotropin (ACTH) and angiotensin-II (A-II)
288. Glucocorticoids enhance corticotropin receptor mRNA levels in ovine adrenocortical cells
289. The mouse adrenocorticotropin receptor gene: Cloning and characterization of its promoter and evidence for a role for the orphan nuclear receptor steroidogenic factor 1
290. Cloning and sequence analysis of the human/31-adrenergic receptor 5′-flanking promoter region
291. Functional analysis of the 5′ flanking sequence in the ovine β1-adrenergic receptor gene
292. Thyroid hormone regulation of β-adrenergic receptor number
293. Fat cell adenylate cyclase and β-adrenergic receptors in altered thyroid states
294. Down-regulation of β-adrenergic receptors: Agonist-induced reduction in receptor mRNA levels
295. Glucocorticosteroids increase β 2-adrenergic receptor transcription in human lung
296. Evidence that glucocorticoid response elements in the 5′-noncoding region of the hamster beta 2-adrenergic receptor gene are obligate for glucocorticoid regulation of receptor mRNA levels
297. Protective effects of a glucocorticoid on downregulation of pulmonary β 2-adrenergic receptors in vivo
298. Desensitization of the human β1-adrenergic receptor. Involvement of the cyclic AMP-dependent but not a receptor-specific protein kinase
299. Cell-specific down-regulation of the β3-adrenergic receptor
300. β-arrestin: A protein that regulates β-adrenergic receptor function
301. A novel human luteinizing hormone receptor gene
302. Regulation of function of the murine luteinizing hormone receptor promoter by cis- and trans-acting elements in mouse Leydig tumor cells
303. cis-acting elements and trans-acting proteins in the transcription of chorionic gonadotropin/luteinizing hormone receptor gene in human choriocarcinoma cells and placenta
304. Analysis of the promoter of the luteinizing hormone/human chorionic gonadotropin receptor gene in neuroendocrine cells
305. Sensitivities of rat kidney thick ascending limbs and collecting ducts to vasopressin in vivo
306. Vasopressin receptor-adenylate cyclase interactions: A model for cAMP metabolism in the kidney
307. Vasopressin, oxytocin and angiotensin receptors in mammals
308. The activation of liver glycogen phosphorylase by vasopressin
309. The cloned vasopressin V1a receptor stimulates phospholipase A2, phospholipase C, and phospholipase D through activation of receptoroperated calcium channels
310. Evidence for glucocorticoid regulation of the rat vasopressin V1a receptor gene
311. Glucocorticoid regulation of vasopressin V1a receptors in rat forebrain
312. Molecular cloning and expression of a rat V1a arginine vasopressin
313. Positive and negative regulation of the rat vasopressin gene promoter
314. Glucocorticoids regulate V1a vasopressin receptor expression by increasing mRNA stability in vascular smooth muscle cells
315. Upregulation of V1a vasopressin receptors by glucocorticoids
316. Glucocorticoid amplifies vasopressin-induced phosphoinositide hydrolysis in aortic smooth muscle cells
317. Glucocorticoids increase vasopressin V1b receptor coupling to phospholipase C
318. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells
319. Functional GIP receptors are present on adipocytes
320. Gastric inhibitory polypeptide stimulates glucocorticoid secretion in rats, acting through specific receptors coupled with the adenylate cyclase-dependent signaling pathway
321. Chronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic rats
322. Structure of the rat glucose-dependent insulinotropic polypeptide receptor gene
323. Cloning, expression, and pharmacology of four human 5-hydroxytryptamine 4 receptor isoforms produced by alternative splicing in the carboxyl terminus
324. Rearrangement and overexpression of D11S287E, a candidate oncogene on chromosome 11q13 in benign parathyroid tumors
325. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension
326. Multiple endocrine neoplasia
327. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-Chernobyl papillary thyroid carcinomas: Biological, phenotypic, and clinical implications
328. Translocation t(10;14)(q11.2:q22.1) fusing the kinetin to the RET gene creates a novel rearranged form (PTC8) of the RET proto-oncogene in radiation-induced childhood papillary thyroid carcinoma
329. Cretinism with combined hormone deficiency caused by a mutation in the PIT1 gene
330. Elevated luteinizing hormone induces expression of its receptor and promotes steroidogenesis in the adrenal cortex
331. Ad4BP/SF-1, a transcription factor essential for the transcription of steroidogenic cytochrome P450 genes and for the establishment of the reproductive function
332. Biochemical diversity of cAMP-dependent transcription of steroid hydroxylase genes in the adrenal cortex
333. Identical origin of adrenal cortex and gonad revealed by expression profiles of Ad4BP/SF-1
334. The ontogenesis of the steroidogenic tissues
335. An unusual member of the nuclear hormone receptor superfamily responsible for X-linked adrenal hypoplasia congenita
336. Mutations in the DAX-1 gene give rise to both X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism
337. A transcriptional silencing domain in DAX-1 whose mutation causes adrenal hypoplasia congenita
338. Steroidogenic factor 1 and Dax-1 colocalize in multiple cell lineages: Potential links in endocrine development
339. Mouse Dax1 expression is consistent with a role in sex determination as well as in adrenal and hypothalamus function
340. Orphan nuclear receptors: From gene to function
341. The murine Dax-1 promoter is stimulated by SF-1 (steroidogenic factor-1) and inhibited by COUP-TF (chicken ovalbumin upstream promoter-transcription factor) via a composite nuclear receptor-regulatory element
342. Dax-1 as one of the target genes of Ad4BP/SF-1
343. The genetics of Wilms' tumor-a case of disrupted development
344. Transcriptional regulation of gene expression: Mechanisms and pathophysiology
345. YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal gland and throughout nephrogenesis
346. YAC transgenic analysis reveals Wilms' tumour 1 gene activity in the proliferating coelomic epithelium, developing diaphragm and limb
347. Wilms' tumor 1 and Dax-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression
348. G proteincoupled receptor systems involved in cell growth and oncogenesis
349. Mutations in G proteins and G protein-coupled receptors in endocrine disease
350. The expanding spectrum of G protein diseases
351. Growth hormonereleasing factor stimulates proliferation of somatotrophs in vitro
352. The cyclic AMP-mediated stimulation of cell proliferation
353. Thyroid expression of an A2 adenosine receptor transgene induces thyroid hyperplasia and hyperthyroidism
354. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas
355. Brief report: Congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene
356. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty
357. Association of a human G-protein β3 subunit variant with hypertension
358. Two G protein oncogenes in human endocrine tumors
359. Gsα - Identification of a gene highly expressed by insulinoma and other endocrine tumors
360. Potentiation of βadrenergic signaling by gene transfer
361. Constitutively active stimulatory G-protein αs in β-cells of transgenic mice causes counterregulation of the increased adenosine 3′,5′-monophosphate and insulin secretion
362. Isoproterenol response following transfection of the mouse β2-adrenergic receptor gene into Y1 cells
363. Direct luteinizing hormone action triggers adrenocortical tumorigenesis in castrated mice transgenic for the murine inhibin α-subunit promoter/simian virus 40 T-antigen fusion gene
364. Are activating mutations of the adrenocorticotropin receptor involved in adrenal cortical neoplasia?
365. Deletion of the adrenocorticotropin receptor gene in human adrenocortical tumors: Implications for tumorigenesis
366. p53 mutations in human adrenocortical neoplasms: Immunohistochemical and molecular studies
367. Expression of adrenocorticotrophic hormone receptor mRNA in human adrenocortical neoplasms: Correlation with P450 scc expression
368. ACTH receptor mRNA in human adrenocortical tumors: Overexpression in aldosteronomas
369. Adenyl cyclase hormone responses of certain human endocrine tumors
370. A glucagon sensitive adenyl cyclase system in pheochromocytoma
371. Characterization of the glucagon receptor in a pheochromocytoma
372. Inadvertent diagnosis of pheochromocytoma after endoscopic premedication
373. Adenylate cyclase of GH and ACTH producing tumors of human: Activation by non-specific hormones and other bioactive substances
374. Growth hormone dynamics in acromegaly
375. Increase of serum growth hormone concentration following thyrotropin-releasing hormone injection in patients with acromegaly or gigantism
376. The spectrum of pituitary growth hormone responses to pharmacological stimuli in acromegaly
377. A novel transcript for the thyrotropin-releasing hormone receptor in human pituitary and pituitary tumors
378. Structure of the thyrotrophin-releasing hormone receptor in human pituitary adenomas
379. Expression of thyrotropin-releasing hormone (TRH) receptor mRNA in somatotrophs in the rat anterior pituitary
380. Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness
381. Endocrine studies in an arrhenoblastoma responsive to dexamethasone. ACTH and human chorionic gonadotropin
382. Steroid production and metabolism in metastatic arrhenoblastoma
383. Adenylate cyclase of a human medullary thyroid carcinoma
384. Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression
385. Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues
386. Pituitary adenylate cyclase-activating polypeptide receptors of types I and II and glucagon-like peptide-I receptors are expressed in the rat medullary carcinoma of the thyroid cell line 6/23
387. Effects of glucagon and glucagon-like peptide-1-(7-36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line
388. Sex-steroid hormone receptors in human medullary thyroid carcinoma
389. Expression of cholecystokinin-B/gastrin receptors in medullary thyroid cancer
390. Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma
391. Effect of atrial natriuretic peptide on catecholamine release from human pheochromocytoma
392. Insulin-like growth factor-II: Possible local growth factor in pheochromocytoma
393. v-Crk modulation of growth factor-induced PC12 cell differentiation involves the Src homology 2 domain of v-Crk and sustained activation of the Ras/mitogen-activated protein kinase pathway
394. Expression of transforming growth factor a and its receptor in human neuroendocrine tumours
395. The CDK inhibitor p21WAF1/Cip1 is induced through a p300-dependent mechanism during NGF-mediated neuronal differentiation of PC12 cells
396. Long-term suppression of testosterone after treatment with a gonadotropin-releasing hormone agonist in a woman with a presumed testosterone secreting ovarian tumor
397. Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing receptor gene mutation
398. A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia
399. Familial gestational hyperthyroidism caused by a mutant thyrotropin receptor hypersensitive to human chorionic gonadotropin
400. Hyperthyroidism
401. Hypoglycemia including hypoglycemia in neonates and children
402. Hormone signaling via membrane receptors
403. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours
404. Genetic alterations in thyroid hyperfunctioning adenomas
405. Rapid GDP release from Gsα in patients with gain and loss of endocrine function